Taysha Gene Therapies, Inc.
TSHA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $376,836 | $357,972 | $346,004 | $1,527,885 |
| - Cash | $139,036 | $143,940 | $87,880 | $149,103 |
| + Debt | $63,559 | $61,107 | $59,928 | $63,092 |
| Enterprise Value | $301,359 | $275,139 | $318,052 | $1,441,874 |
| Revenue | $8,333 | $15,451 | $2,502 | $0 |
| % Growth | -46.1% | 517.5% | – | – |
| Gross Profit | $8,333 | $15,451 | $15 | $0 |
| % Margin | 100% | 100% | 0.6% | – |
| EBITDA | -$87,951 | -$105,197 | -$159,729 | -$172,603 |
| % Margin | -1,055.5% | -680.8% | -6,384.1% | – |
| Net Income | -$89,298 | -$111,566 | -$166,014 | -$174,523 |
| % Margin | -1,071.6% | -722.1% | -6,635.3% | – |
| EPS Diluted | -0.357 | -0.961 | -3.777 | -4.635 |
| % Growth | 62.8% | 74.6% | 18.5% | – |
| Operating Cash Flow | -$81,225 | -$73,018 | -$88,390 | -$117,042 |
| Capital Expenditures | -$374 | -$7,369 | -$24,869 | -$21,554 |
| Free Cash Flow | -$81,599 | -$80,387 | -$113,259 | -$138,596 |